Business Wire

European Commission Grants Marketing Authorisation for MSD’s ZEPATIER™ (elbasvir/grazoprevir) for the Treatment of Chronic Hepatitis C Infection

Del

MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK)) today announced that the European Commission has approved ZEPATIER™ (elbasvir/grazoprevir) with or without ribavirin (RBV) for the treatment of chronic hepatitis C virus (HCV) genotype (GT) 1 or GT4 infection in adults. ZEPATIER is MSD’s once-daily, fixed-dose combination tablet containing the NS5A inhibitor elbasvir (50mg) and the NS3/4A protease inhibitor grazoprevir (100mg). This approval allows marketing of ZEPATIER tablets in the 28 countries that are members of the European Union, as well as European Economic Area members, Iceland, Liechtenstein and Norway. MSD continues to work to supply the EU market, with product launches estimated to begin between the fourth quarter of 2016 and the first quarter of 2017. Product launches are expected to continue across the EU through 2017.

“The approval of ZEPATIER in the European Union, following approvals in the United States and Canada earlier this year, is an important step in offering a new and effective treatment for millions of people infected with hepatitis C virus genotype 1 or 4,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories, a U.S.-based division of Merck & Co., Inc., Kenilworth, N.J., USA. “ZEPATIER is the most recent advance from MSD in our more than 30-year effort to combat the effects of hepatitis C virus infection, and hence, to reduce the burden of this disease around the world.”

Thousands of chronic HCV patients worldwide participated in the ZEPATIER clinical development program, which was designed to include patients with known treatment challenges, such as those with compensated cirrhosis and those for whom treatment with peginterferon plus RBV, with or without an HCV protease inhibitor, has not worked. In the trials, overall sustained virologic response (SVR) 12 weeks after the completion of therapy (SVR12, considered virologic cure based on undetectable HCV RNA levels) was achieved in 96 percent (301/312) of chronic HCV GT1b-infected patients treated with ZEPATIER for 12 weeks. In chronic HCV GT1a-infected patients, 93 percent (483/519) and 95 percent (55/58) achieved cure following treatment with ZEPATIER for 12 weeks or ZEPATIER plus RBV for 16 weeks, respectively. Additionally, 94 percent (61/65) and 100 percent (8/8) of chronic HCV GT4-infected patients achieved cure following treatment with ZEPATIER for 12 weeks or ZEPATIER plus RBV for 16 weeks, respectively.

Chronic HCV infection, caused by a blood-borne virus, is a major public health concern affecting more than 170 million people globally, 15 million of whom are living in Europe. Of the six genotypes of chronic HCV infection, GT1 is the most common in Europe accounting for approximately 66 percent of cases, and GT1b infection is the most prevalent sub-genotype in the majority of European countries. In addition, the prevalence of GT4 infection is increasing in Europe.

“Given the complexities of chronic hepatitis C, it is critical to have a variety of effective treatment options to ensure diverse types of patients have the highest possible chance to achieve cure,” said Professor Rafael Esteban, M.D., chief of the internal medicine and liver unit of the Hospital Universitario Val d’Hebron, Barcelona, Spain, and professor of medicine at the Universidad Autonoma de Barcelona. “In clinical trials, ZEPATIER achieved high cure rates among a broad range of chronic hepatitis C patients with genotype 1 or 4 infection, from patients who are treatment-naïve to many of those whose chronic HCV infection has been historically difficult-to-treat, providing an important new option in the fight against this global public health epidemic.”

A 12-week, once-daily regimen is recommended for patients with chronic HCV GT1 or GT4 infection. For certain patients, a regimen of ZEPATIER plus RBV for 16 weeks should be considered. The recommended regimens and durations for treatment with once-daily ZEPATIER in chronic HCV patients with or without compensated cirrhosis (Child-Pugh A only) are included in the chart below. No dose adjustments are required when using ZEPATIER with acid-reducing agents.

HCV Genotype   Treatment and Duration
GT1a  

ZEPATIER for 12 weeks

 

ZEPATIER for 16 weeks plus RBV* should be considered in patients
with baseline HCV RNA level >800,000 IU/ml and/or the presence of specific NS5A
polymorphisms to minimise the risk of treatment failure.

GT1b   ZEPATIER for 12 weeks
GT4  

ZEPATIER for 12 weeks

 

ZEPATIER for 16 weeks plus RBV* should be considered in patients with
baseline HCV RNA level >800,000 IU/ml to minimise the risk of treatment failure.

*In the clinical studies, the dose of RBV was weight-based (<66 kg = 800 mg/day, 66 to 80 kg = 1,000
mg/day, 81 to 105 kg = 1,200 mg/day, >105 kg = 1,400 mg/day) administered in two divided doses with
food.

NS5A polymorphisms, causing at least a 5-fold reduction in activity of elbasvir, included L/M28T/A,
R/Q30E/H/R/G/K/L/D, L31M/V/F, H58D and Y93C/H/N.

“Expanding the treatment landscape is always meaningful for the patient community as we continue to build upon the strides made in recent years to raise awareness of and treat chronic hepatitis C worldwide,” said Charles Gore, president, World Hepatitis Alliance. “Competition helps fuel dialogue and ensure people know chronic hepatitis C is treatable. With new treatment options, more patients may be able to achieve cure, and hopefully share their stories to inspire others to get treated.”

ZEPATIER Clinical Trial Program

The efficacy and safety of ZEPATIER were evaluated in eight clinical studies in approximately 2,000 patients. The development program was designed to investigate ZEPATIER across diverse chronic HCV patients, including those on opioid agonist therapy, with chronic kidney disease or with HCV/HIV-1 co-infection. The primary efficacy endpoint in all studies was SVR12. An overview of the studies is provided below. For full study details, see the Summary of Product Characteristics at http://ec.europa.eu/health/documents/community-register/2016/20160722135308/anx_135308_en.pdf.

Study   Patient Population   Study Arms and Duration

C-EDGE TN

(double-blind)

 

GT1, GT4 or GT6 TN +/-
cirrhosis

 
  • ZEPATIER for 12 weeks (N=316)
  • Placebo for 12 weeks (N=105)

C-EDGE
COINFECTION
(open-label)

 

GT1, GT4 or GT6 TN with
HCV/HIV-1 co-infection +/-
cirrhosis

 
  • ZEPATIER for 12 weeks (N=218)

C-SURFER

(double-blind)

 

GT1 TN or TE with Stage 4 or
Stage 5 chronic kidney disease
+/- cirrhosis

 
  • ZEPATIER* for 12 weeks (N=122,
    including 11 patients in open-label
    intensive PK arm)
  • Placebo for 12 weeks (N=113)

C-WORTHY

(open-label)

 

GT1 or GT3 TN +/- cirrhosis,
TE null responders +/- cirrhosis,

TN with HCV/HIV-1 co-infection
without cirrhosis

 
  • ZEPATIER* for 8, 12 or 18 weeks
    (N=31, 136 and 63, respectively)
  • ZEPATIER* + RBV for 8, 12 or 18
    weeks (N=60, 152 and 65,
    respectively)

C-SCAPE

(open-label)

 

GT4 or GT6 TN without
cirrhosis

 
  • ZEPATIER* for 12 weeks (N=14)
  • ZEPATIER* + RBV for 12 weeks
    (N=14)

C-EDGE TE

(open-label)

 

GT1, GT4 or GT6 TE +/-
cirrhosis, and +/- HCV/HIV-1
co-infection

 
  • ZEPATIER for 12 or 16 weeks
    (N=105 and 105, respectively)
  • ZEPATIER + RBV for 12 or 16
    weeks (N=104 and 106,
    respectively)

C-SALVAGE

(open-label)

 

GT1 TE with HCV protease
inhibitor regimen +/- cirrhosis

 
  • ZEPATIER* + RBV for 12 weeks
    (N=79)

C-EDGE

CO-STAR

(double-blind)

 

GT1, GT4 or GT6 TN on opioid
agonist therapy, +/- cirrhosis

 
  • ZEPATIER for 12 weeks (N=201)
  • Placebo for 12 weeks (N=100)

GT = Genotype

TN = Treatment-Naïve

TE = Treatment-Experienced (failed prior treatment with interferon [IFN] or peginterferon alfa [pegIFN]
with or without RBV or were intolerant to prior therapy)

PK = pharmacokinetic

*Elbasvir 50mg + grazoprevir 100mg co-administered as single agents

RBV was administered at a total daily dose of 800mg to 1,400mg based on weight

Failed prior treatment with boceprevir, telaprevir, or simeprevir in combination with pegIFN + RBV

Important Safety Information about ZEPATIER (elbasvir/grazoprevir)

ZEPATIER is contraindicated in patients with hypersensitivity to the active substances or to any of the excipients and in patients with moderate or severe hepatic impairment (Child-Pugh B or C). Co-administration of ZEPATIER with inhibitors of organic anion transporting polypeptide 1B (OATP1B) or with inducers of cytochrome P450 3A (CYP3A) or p-glycoprotein (P-gp) is also contraindicated.

The rate of late alanine transaminase (ALT) elevations during treatment is directly related to the plasma exposure to grazoprevir. During clinical studies with ZEPATIER with or without RBV, < 1 % of subjects experienced elevations of ALT from normal levels to greater than 5 times the upper limit of normal (ULN). Higher rates of late ALT elevations occurred in females (2 % [11/652]), Asians (2 % [4/165]), and subjects aged ≥ 65 years (2 % [3/187]). These late ALT elevations generally occurred at or after treatment week 8.

Hepatic laboratory testing should be performed prior to therapy, at treatment week 8, and as clinically indicated. For patients receiving 16 weeks of therapy, additional hepatic laboratory testing should be performed at treatment week 12. Patients should be instructed to consult their healthcare professional without delay if they have onset of fatigue, weakness, lack of appetite, nausea and vomiting, jaundice or discoloured faeces. Discontinuation of ZEPATIER should be considered if ALT levels are confirmed to be greater than 10 times the ULN. ZEPATIER should be discontinued if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or international normalised ratio (INR).

ZEPATIER contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product. ZEPATIER contains 3.04 mmol (or 69.85 mg) sodium per dose. To be taken into consideration by patients on a controlled sodium diet.

In clinical studies, the most commonly reported adverse reactions (greater than 10%) were fatigue and headache. Less than 1 % of subjects treated with ZEPATIER with or without RBV had serious adverse reactions (abdominal pain, transient ischaemic attack and anaemia). Less than 1 % of subjects treated with ZEPATIER with or without RBV permanently discontinued treatment due to adverse reactions. The frequency of serious adverse reactions and discontinuations due to adverse reactions in subjects with compensated cirrhosis were comparable to those seen in subjects without cirrhosis.

When ZEPATIER was studied with RBV, the most frequent adverse reactions to ZEPATIER + RBV combination therapy were consistent with the known safety profile of RBV.

Very common (≥ 1/10) adverse reactions identified with ZEPATIER, based on pooled data from patients treated for 12 weeks without RBV, include headache and fatigue. Common (≥ 1/100 to < 1/10) adverse reactions include decreased appetite, insomnia, anxiety, depression, dizziness, nausea, diarrhea, constipation, upper abdominal pain, abdominal pain, dry mouth, vomiting, pruritus, alopecia, arthralgia, myalgia, asthenia, irritability.

Common adverse reactions of fatigue, headache, and nausea occurred at a similar frequency in patients treated with ZEPATIER or placebo.

For detailed information, please visit http://ec.europa.eu/health/documents/community-register/2016/20160722135308/anx_135308_en.pdf.

MSD’s Commitment to HCV and Treatment Access

For more than 30 years, MSD has been at the forefront of the response to chronic HCV infection, and we continue to work to advance scientific understanding of this significant global public health epidemic. MSD’s chronic HCV clinical development programs have included more than 135 clinical trials in approximately 40 countries and have enrolled nearly 10,000 participants.

MSD believes scientific advancements must be supported by a commitment to access to make a meaningful difference in the lives of patients. While the latest innovations in chronic HCV treatment that have become available over recent years provide Europe with an unprecedented opportunity to significantly reduce the burden of HCV, an urgent medical need remains. It is estimated that less than one in five diagnosed chronic HCV patients are currently treated in the largest countries within Europe (France, Germany, Italy, Spain and United Kingdom), with thousands of new cases each year. As part of our longstanding leadership in infectious disease and experience in delivering market-defined access programs, MSD will continue to collaborate with stakeholders to ensure ZEPATIER is an option for all patients for whom it is indicated. Together, we believe we can facilitate the collective goal of addressing the global burden of chronic HCV.

About MSD

For 125 years, MSD has been a global health care leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., Kenilworth, N.J., USA. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

# # #

Please see European Summary of Product Characteristics for ZEPATIER (elbasvir/grazoprevir) at http://ec.europa.eu/health/documents/community-register/2016/20160722135308/anx_135308_en.pdf .

Contact information

Merck
Media:
Pamela Eisele, +1 267 305 3558
or
Sarra Herzog, +1 201 669 6570
or
Investors:
Teri Loxam, +1 908 740 1986
or
Amy Klug, +1 908 740 1898

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Ferring Pharmaceuticals and MSD Announce Completion of Largest Clinical Trial Ever Conducted in Postpartum Haemorrhage22.2.2018 06:00Pressemelding

Ferring Pharmaceuticals and MSD, known as Merck & Co., Inc., Kenilworth, N.J., U.S.A., through its MSD for Mothers initiative, today announced the completion of CHAMPION (Carbetocin Haemorrhage Prevention), a global clinical trial conducted by the Human Reproduction Program (HRP) at the World Health Organization (WHO). CHAMPION is investigating whether Ferring’s proprietary and heat-stable carbetocin could offer a new solution to prevent excessive bleeding after childbirth (postpartum haemorrhage or PPH).2,3 Involving nearly 30,000 women in 10 countries, it is the largest clinical trial ever conducted in PPH.2,3 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221006496/en/ Each year, 14 million mothers are affected by PPH.4 As the leading direct cause of maternal mortality, 480,000 mothers died from PPH between 2003-09.1 Even when women survive, PPH can result in the need for serious medical interventions, including surgica

The Nippon Foundation: Project to Map Ocean Floor by 2030 Now Operational22.2.2018 05:00Pressemelding

The Nippon Foundation Chairman Yohei Sasakawa announced at a press conference today that The Nippon Foundation – GEBCO Seabed 2030 Project is now operational. The Project will realize Mr. Sasakawa’s vision of mapping the entire ocean floor by 2030. The Nippon Foundation has pledged US$2 million annually, and is calling for additional support from the global ocean community. Mr. Sasakawa noted, “The Nippon Foundation alone cannot achieve the objectives of this ambitious project. We will need the support of diverse stakeholders, including maritime corporations and technical experts. It is crucial that the ocean community comes together to achieve this goal”. He was joined by leading ocean-mapping experts, who emphasized that understanding the bathymetry of the global ocean is imperative for improving maritime navigation, and also for enhancing our ability to predict climate change and monitor marine biodiversity and resources. A comprehensive map of the seafloor will assist global effort

Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis21.2.2018 21:01Pressemelding

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it is initiating the first Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation. The study will enroll 360 patients, and the primary endpoint of the study is the mean absolute change from baseline in percent predicted forced expiratory volume in one second (ppFEV1) at week four of treatment. The study is designed to support the submission of a New Drug Application (NDA) in the U.S. using data from the 4-week primary efficacy endpoint together with safety data through 12 weeks of treatment. “Our goal is to bring the best triple combination to patients as rapidly as possible, and this first Phase 3 study of VX-659 in combination with tezacaftor and ivacaftor is a significant step toward that goal,” said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical

Universal Laser Systems® Expands Portfolio of Laser Material Processing Systems with the ULTRA Platform Series21.2.2018 18:00Pressemelding

ULTRA platform-based laser systems are designed and ideally suited for precision laser cutting, laser ablation, and laser surface modification in manufacturing, research and development, academic research and prototyping environments. Major features of the series include rapid, high-accuracy laser beam positioning, and the flexibility to be configured with 9.3 and 10.6 µm CO2 lasers and 1.06 µm fiber lasers. All lasers are air-cooled in a range of power from 10 to 150 watts for CO2 and 40 to 50 watts for fiber lasers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005364/en/ The ULTRA 9MW offers MultiWave processing of thin materials. (Photo: Business Wire) The variety of wavelengths and power ranges make the ULTRA platforms highly effective in the areas of organic material modification, including plastic films, industrial fabrics, engineering plastics, laminating adhesives, composite materials, and many others utilized

Luxoft One of Six Companies Collaborating with Amazon Web Services to Accelerate Blockchain Adoption21.2.2018 16:30Pressemelding

Luxoft Holding Inc (NYSE:LXFT), a global IT service provider, announces today that it is collaborating with Amazon Web Services (AWS) to enable corporates to adopt blockchain and Distributed Ledger Technologies (DLT). Luxoft is one of six IT and consulting services companies to make its blockchain advisory and development services available to AWS users. “We are very excited to be working with AWS to help users engage with blockchain and DLTs,” said Vasiliy Suvorov, Vice President of Technology Strategy at Luxoft. “Blockchain is about removing data silos, improving trust and operational efficiencies. By using AWS to deploy and integrate DLTs into day-to-day processes, businesses can revolutionize how they operate.” Luxoft helps accelerate the deployment and integration of blockchain and DLT-based projects on AWS and is already working on a number of DLT projects using the cloud. For example, Luxoft is building a healthcare claims processing system for a leading healthcare provider usin

Westinghouse Electric Company to Provide Engineering Support at Vandellós 1 in Partnership with EDF21.2.2018 16:30Pressemelding

Westinghouse Electric Company and Electricité de France (EDF), in partnership, announced today that they have been awarded a contract from Empresa Nacional de Residuos Radiactivos (ENRESA), the Spanish agency responsible for radioactive waste management and nuclear plant decommissioning. The agreement covers a four-year engineering support contract for the latency phase of the dismantling and decommissioning project at Vandellós I Nuclear Power Station in Spain and includes the preparation of technical and licensing documentation. “We are extremely pleased that ENRESA has selected Westinghouse and EDF to continue supporting the decommissioning activities at Vandellós I Nuclear Power Station,” said Yves Brachet, Westinghouse vice president, Global Decommissioning, Decontamination, Remediation and Waste Management. “This contract further demonstrates Westinghouse’s global capabilities and expertise in providing innovative decommissioning solutions.” Sylvain Granger, head of EDF's decommi